Alkermes Competitors and Similar CompaniesClear all

Alkermes's competitors and similar companies include UCB, EMS Pharma and Cipla.

	Alkermes Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system diseases.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	EMS Pharma EMS Pharma is a company that specializes in the research, development, and manufacturing of pharmaceuticals.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 1987	Founding Date 1928	Founding Date 1964	Founding Date 1935
Type	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Dublin, IE HQ Westmeath, IE Waltham, US Wilmington, US	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations BR HQ	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 1,800	Employees 9,052	Employees 12,7441% increase	Employees 27,764
Valuation ($)	Valuation ($) 4.3 b	Valuation ($) 34.3 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $1.5b (FY, 2025)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods $196.5m (FY, 2025)	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A	Cost of goods ₹95.5b (FY, 2026)
Gross profit	Gross profit $1.3b (FY, 2025)	Gross profit €7.2b (FY, 2025)	Gross profit N/A	Gross profit ₹195b (FY, 2026)
Net income	Net income $241.7m (FY, 2025)	Net income €1.6b (FY, 2025)	Net income N/A	Net income ₹38.7b (FY, 2026)